Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.

Autor: You X; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI., Liu F; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI., Binder M; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Vedder A; Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Lasho T; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Wen Z; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI., Gao X; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI., Flietner E; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI., Rajagopalan A; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI., Zhou Y; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI., Finke C; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Mangaonkar A; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Liao R; Department of Cell and Regenerative Biology and., Kong G; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI., Ranheim EA; Department of Pathology and Laboratory Medicine, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Droin N; INSERM U981, Gustave Roussy Cancer Center, Villejuif, France., Hunter AM; Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA., Nikolaev S; INSERM U981, Gustave Roussy Cancer Center, Villejuif, France., Balasis M; Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Abdel-Wahab O; Human Oncology and Pathogenesis Program.; Leukemia Service, Department of Medicine.; Center for Hematologic Malignancies, and.; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY., Levine RL; Human Oncology and Pathogenesis Program.; Leukemia Service, Department of Medicine.; Center for Hematologic Malignancies, and.; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY., Will B; Department of Medicine, Albert Einstein College of Medicine, Bronx, NY., Nadiminti KVG; Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI., Yang D; Department of Pathology and Laboratory Medicine, Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI., Geissler K; Medical School, Sigmund Freud University, Vienna; Austria., Solary E; INSERM U1287 and Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France; and.; Faculté de Médecine, Le Kremlin-Bicêtre, Université Paris-Saclay, Paris, France., Xu W; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI., Padron E; Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN., Zhang J; McArdle Laboratory for Cancer Research, University of Wisconsin School of Medicine and Public Health, Madison, WI.

Publikováno v: Blood [Blood] 2022 Feb 17; Vol. 139 (7), pp. 1066-1079.